Use of label-free protein chips for proteomics of oncohematological diseases

Česká verzia

Authors: K. Pimková ^1,2; J. Suttnar ¹; M. Bockova ²; J. Homola ²; J. E. Dyr ¹
Authors place of work: Oddělení biochemie Ústavu hematologie a krevní transfuze Praha, vedoucí oddělení biochemie prof. Ing. Jan E. Dyr, DrSc. ¹; Oddělení optických senzorů Ústavu fotoniky a elektroniky Praha, vedoucí oddělení optických senzorů doc. Ing. Jiří Homola, DrSc. ²
Published in the journal: Vnitř Lék 2012; 58(Suppl 2): 84-89
Category:

Summary

Despite great advances in our understanding of the molecular basis of many diseases, there are still substantial gaps in our understanding of oncohematological diseases as well as in the development of effective strategies for early diagnosis and for treatment. The current interest in proteomics is growing partly due to the prospects that proteomic methods offer and hopefully overcome limitations of other approaches. At the Institute of Hematology and Blood Transfusion the proteomics of oncohematological diseases, especially myelodysplastic syndrome and chronic myeloid leukaemia, has been studied. This work gives an overview of development and importance of proteomics for studying the oncohematological diseases. Furthermore, it introduces several new methods applied in proteomics, deals with problems attached to working with complex biological samples, and at the end describes our latest development of a protein chip with on-line detection using an optical method – the surface plasmon resonance – for characterizing MDS pathogenesis.

Key words:
proteomics – myelodysplastic syndromes – oncohematological diseases – surface plasmon resonance

Zdroje

1. McKusick VA. Genomics: structural and functional studies of genomes. Genomics 1997; 45: 244–249.

2. Wilkins MR, Pasquali C, Appel RD et al. From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996; 14: 61–65.

3. Riedel T, Suttnar J, Brynda E et al. Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 2011; 117: 1700–1706.

4. Majek P, Reicheltova Z, Stikarova J et al. Proteome changes in platelets activated by arachidonic acid, collagen, and thrombin. Proteome Sci 2010; 8: 56.

5. Sobotkova A, Masova-Chrastinova L, Suttnar J et al. Antioxidants change platelet responses to various stimulating events. Free Radic Biol Med 2009; 47: 1707–1714.

6. Maly MA, Majek P, Reicheltova Z et al. Proteomic analysis of plasma samples from acute coronary syndrome patients – The pilot study. Int J Cardiol 2012; 157: 126–128.

7. Majek P, Reicheltova Z, Suttnar J et al. Plasma proteome changes in cardiovascular disease patients: novel isoforms of apolipoprotein A1. J Transl Med 2011; 9: 84.

8. Micallef J, Dharsee M, Chen J et al. Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J Hematol Oncol 2012; 3: 13.

9. Majek P, Reicheltova Z, Suttnar J et al. Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci 2011; 9: 64.

10. Merkerova MD, Bystricka D, Belickova M et al. From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype. Genes Chromosomes Cancer 2012; 51: 419–428.

11. Votavova H, Grmanova M, Dostalova Merkerova M et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011; 4: 1.

12. Lopotova T, Nadvornikova S, Zackova M et al. N-terminally truncated WT1 variant (sWT1) is expressed at very low levels in acute myeloid leukemia and advanced phases of chronic myeloid leukemia. Leuk Res 2012; 36: e81–e83.

13. Machova Polakova K, Lopotova T, Klamova H et al. Expression patterns of microRNAs associated with CML phases and their disease related targets. Mol Cancer 2011; 10: 41.

14. Gorg A, Postel W, Gunther S. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1988; 9: 531–546.

15. Fenn JB, Mann M, Meng CK et al. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989; 246: 64–71.

16. Karas M, Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal Chem 1988; 60: 2299–2301.

17. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000; 289: 1760–1763.

18. Ray S, Mehta G, Srivastava S. Label-free detection techniques for protein microarrays: prospects, merits and challenges. Proteomics 2010; 10: 731–748.

19. Jiang SY, Cao ZQ. Ultralow-Fouling, Functionalizable, and Hydrolyzable Zwitterionic Materials and Their Derivatives for Biological Applications. Adv Mater 2010; 22: 920–932.

20. Krishnan S, Weinman CJ, Ober CK. Advances in polymers for anti-biofouling surfaces. J Mater Chem 2008; 18: 3405–3413.

21. Hucknall A, Rangarajan S, Chilkoti A. In Pursuit of Zero: Polymer Brushes that Resist the Adsorption of Proteins. Adv Mater 2009; 21: 2441–2446.

22. Ahmed N, Barker G, Oliva K et al. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003; 3: 1980–1987.

23. Lei T, He QY, Wang YL et al. Heparin chromatography to deplete high-abundance proteins for serum proteomics. Clin Chim Acta 2008; 388: 173–178.

24. Pieper R, Su Q, Gatlin CL et al. Multi-component immunoaffinity subtraction chromatography: An innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 2003; 3: 422–432.

25. Martosella J, Zolotarjova N, Liu HB et al. Reversed-phase high-performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lower-abundant proteins. J Proteome Res 2005; 4: 1522–1537.

26. Righetti PG, Boschetti E. The Proteominer and the Fortyniners: Searching for Gold Nuggets in the Proteomic Arena. Mass Spectrom Rev 2008; 27: 596–608.

27. Piliarik M, Bockova M, Homola J. Surface plasmon resonance biosensor for parallelized detection of protein biomarkers in diluted blood plasma. Biosens Bioelectron 2010; 26: 1656–1661.

28. Pimkova K, Bockova M, Hegnerova K et al. Surface plasmon resonance biosensor for the detection of VEGFR-1 – a protein marker of myelodysplastic syndromes. Anal Bioanal Chem 2012; 402: 381–387.